Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bosutinib for the Treatment of CML-Using it Safely: a Podcast.
Target Oncol
January 2025
Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.
View Article and Find Full Text PDFEvaluation of the Impact of Breast Radiation Therapy on Quality of Life Requires Appropriate Instruments at Relevant Timepoints.
Clin Breast Cancer
December 2024
Department of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hospital Authority, Hong Kong S.A.R., China. Electronic address:
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Lancet Oncol
January 2025
Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Veterans Affairs Center for Clinical Management Research, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology and Lung Precision Oncology Program, University of Michigan Division of Hematology/Oncology, Rogel Cancer Center, Institute for Health Policy and Innovation, and Center for Global Health Equity, Ann Arbor, MI, USA.
Description of implementing a mail-based overdose education and naloxone distribution program in community supervision settings during COVID-19.
J Subst Use Addict Treat
December 2024
Department of Pharmacy Practice & Science, Center for the Advancement of Pharmacy Practice, University of Kentucky, 789 S. Limestone, Lexington, KY 40508, USA. Electronic address:
Introduction: This study uses the Exploration, Preparation, Implementation, and Sustainment (EPIS) model to retrospectively describe the mail-based overdose education and naloxone distribution (OEND) program developed in collaboration with the Kentucky Department of Corrections (DOC) for use in the HEALing Communities Study in Kentucky (HCS-KY) and details the reach of this innovative delivery model.
Methods: HCS-KY is a community-engaged cluster-randomized trial assessing the effects of implementing evidence-based practices, including OEND, on overdose death reduction across 16 communities highly impacted by the opioid epidemic in Kentucky. The study launch coincided with the COVID-19 pandemic.
Reply: The pulmonary sulcus phenomenon in lung cancer invading the chest wall.
J Thorac Cardiovasc Surg
December 2024
Toronto General Hospital and Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!